Amicus Brief Filed in RPX Corp. v. Chanbond LLC: Patient and public interest actors should have the same rights as drugmakers to appeal IPR decisions to the courts to prevent unmerited patents.
Letter to the USPTO Director
Policy Prescriptions to Solve the Drug Patent Problem
Submission to Chinese FDA: more exclusivity will harm patients
The importance of patent oppositions in assisting patent examination
Presentation by Tahir Amin at the Global Summit on Intellectual Property & Access to Medicines in the parallel session “Preventing bad patents: The role of patent examination.”
America’s Overspend: How the Pharmaceutical Patent Problem is Fueling High Drug Prices
The American health system is poised to incur $55 billion in excess costs from pharmaceutical companies’ strategies to delay competition on three drugs
Policy Brief: How the Supreme Court Patent Case Could Raise Drug Prices
With the majority of voters on both sides of the aisle saying Congress’s top priority should be lowering high drug costs, an upcoming U.S. Supreme Court case could significantly hamper the country’s ability to lower the price of medicine and assess and remove unmerited pharmaceutical patents. This policy brief examines the little-discussed health implications of…
FDA Submission for Administering The Hatch-Waxman Amendments: Ensuring A Balance Between Innovation And Access
“Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access” was a meeting held on July 18, 2017 to provide the public an opportunity to submit comments concerning administration of the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act) to help ensure the intended balance between encouraging innovation in drug…
Challenges To India’s Pharmaceutical Patent Laws, Science Policy Forum
Briefing Memo: Risks Of The Trans-Pacific Free Trade Agreement For Access To Medicines – Analysis Of The Leaked U.S. Paper Eliminating Patent Pre-Grant Opposition
A leaked U.S. paper recently circulated to countries negotiating the TransPacific Partnership Agreement (TPPA) outlines the U.S. argument for eliminating “pre-grant opposition,” an important tool for preventing patent applicants from gaining patent monopolies based on weak or erroneous information, for improving the quality and efficiency of patent office examinations, and for safeguarding access to medicines.